Eli Lilly trial update on kidney drug hurts Tectonic

cafead

Administrator
Staff member
  • cafead   Jan 28, 2025 at 09:42: PM
via Shares of Tectonic Therapeutic (NASDAQ:TECX) plunged on Tuesday after a federal website on clinical trials indicated that Eli Lilly (NYSE:LLY) has terminated a mid-stage trial for its experimental kidney disease therapy volenrelaxin, a treatment similar to TECX's lead asset TX45.

article source